Spikevax Bivalent Original/Omicron BA.4-BA.5 (elasomeran/davesomeran) / Moderna - LARVOL DELTA

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine (clinicaltrials.gov) - P=N/A | N=1169 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Infectious Disease • Inflammation • Novel Coronavirus Disease

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran (clinicaltrials.gov) - P=N/A | N=15196685 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed | N=10000000 ➔ 15196685

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran (clinicaltrials.gov) - P=N/A | N=10000000 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=152 | Terminated | Sponsor: Jules Bordet Institute | N=440 ➔ 152 | Trial completion date: Dec 2024 ➔ Jan 2024 | Recruiting ➔ Terminated; The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=440 | Recruiting | Sponsor: Jules Bordet Institute

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Elasomeran+davesomeran for prevention of COVID-19. (PubMed, Aust Prescr) - No abstract available

Journal • Review • Infectious Disease • Novel Coronavirus Disease

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran (clinicaltrials.gov) - P=N/A | N=10000000 | Recruiting | Sponsor: ModernaTX, Inc.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine (clinicaltrials.gov) - P=N/A | N=1500 | Active, not recruiting | Sponsor: ModernaTX, Inc.

New trial • Cardiovascular • Infectious Disease • Inflammation • Novel Coronavirus Disease